OTCMKTS:UCBJF UCB (UCBJF) Stock Price, News & Analysis → Write this ticker symbol down… (From StocksToTrade) (Ad) Free UCBJF Stock Alerts $132.00 +0.85 (+0.65%) (As of 05/10/2024) Add Compare Share Share Today's Range$132.00▼$132.5050-Day Range$122.00▼$133.6852-Week Range$69.70▼$133.68Volume600 shsAverage Volume363 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartFinancialsHeadlinesSEC FilingsShort Interest Get UCB alerts: Email Address Ad StocksToTradeWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything.Discover the #1 company leading this revolution About UCB Stock (OTCMKTS:UCBJF)UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.Read More UCBJF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart UCBJF Stock News HeadlinesApril 25, 2024 | msn.comUCB SA goes ex dividend tomorrowApril 24, 2024 | seekingalpha.comArtisan Global Equity Fund Q1 2024 CommentaryApril 24, 2024 | seekingalpha.comArtisan International Fund Q1 2024 CommentaryMarch 22, 2024 | finance.yahoo.comUCB Convening Notice to the General Meeting of the Shareholders 2024March 7, 2024 | realmoney.thestreet.comUCB price target raised by EUR 13 at BarclaysFebruary 28, 2024 | msn.comUCB SA reports FY resultsFebruary 10, 2024 | marketwatch.comStocks A-ZFebruary 4, 2024 | msn.comInvestors growing more bullish on SMID cap biotech stocksNovember 14, 2023 | msn.comUCB launches newly approved psoriasis drug Bimzelx in USNovember 11, 2023 | finance.yahoo.comPost Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)November 10, 2023 | finance.yahoo.comUCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023October 18, 2023 | finance.yahoo.comBIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque PsoriasisOctober 18, 2023 | finance.yahoo.comUCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravisOctober 13, 2023 | finance.yahoo.comUCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023October 12, 2023 | finance.yahoo.comPhase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis SuppurativaJune 27, 2023 | finance.yahoo.comFDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in AdultsFebruary 22, 2023 | finance.yahoo.comChina Anti-Rheumatic Drug Markets Report 2022-2027 Featuring Pfizer, F. Hoffmann-La Roche, UCB S.A., Eli Lilly and Company, & AbbVie Inc.October 20, 2022 | finance.yahoo.comUCB SA (UCBJF)April 25, 2022 | finance.yahoo.comHere's Why Momentum in UCB SA (UCBJF) Should Keep goingMarch 31, 2022 | msn.comWhat Makes UCB SA (UCBJF) a Good Fit for "Trend Investing"March 25, 2022 | finanznachrichten.deUCB SA/NV - CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS 2022February 7, 2022 | seekingalpha.comBiogen signs licensing deal with Xbrane for potential biosimilar to CimziaJanuary 23, 2022 | finance.yahoo.comZGNX Jan 2022 7.000 callJanuary 21, 2022 | msn.comWhy Zogenix Flew Higher Before Leveling Off This WeekJanuary 19, 2022 | markets.businessinsider.comUCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The HighlightsSee More Headlines Receive UCBJF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for UCB and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/10/2024Next Earnings (Estimated)7/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:UCBJF CUSIPN/A CIK1290640 Webwww.ucb.com Phone(322) 559-9999Fax32-2559-9900Employees8,703Year Founded1928Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$5.27 billion Price / SalesN/A Cash Flow$7.90 per share Price / Cash Flow16.70 Book Value$50.52 per share Price / Book2.61Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.48 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Jean-Christophe Tellier (Age 65)CEO & Executive Director Comp: $4.44MMs. Sandrine Dufour CFA (Age 58)Executive VP, CFO & Chief Corporate Development Dr. Kirsten Lund-Jurgensen Ph.D. (Age 64)Executive Vice President of Supply & Technology Solutions Ms. Denelle J. Waynick Johnson J.D. (Age 57)Executive VP & General Counsel Mr. Jean-Luc Fleurial (Age 59)Executive VP & Chief Human Resources Officer Prof. Iris Loew-Friedrich (Age 64)Executive VP & Chief Medical Officer Mr. Emmanuel Caeymaex (Age 55)Executive VP & Chief Commercial Officer Ms. Fiona du Monceau (Age 46)Executive Vice President of Patient Evidence Comp: $177.53kMs. Caroline VancoillieChief Accounting Officer, Head of Group Finance & CFO of Patient Value FunctionsMr. Alistair Henry (Age 57)Executive VP & Chief Scientific Officer More ExecutivesKey CompetitorsCSLOTCMKTS:CSLLYGSKNYSE:GSKBristol-Myers SquibbNYSE:BMYZoetisNYSE:ZTSTakeda PharmaceuticalNYSE:TAKView All Competitors UCBJF Stock Analysis - Frequently Asked Questions Should I buy or sell UCB stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for UCB in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" UCBJF shares. View UCBJF analyst ratings or view top-rated stocks. How have UCBJF shares performed in 2024? UCB's stock was trading at $87.10 on January 1st, 2024. Since then, UCBJF stock has increased by 51.5% and is now trading at $132.00. View the best growth stocks for 2024 here. When is UCB's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 24th 2024. View our UCBJF earnings forecast. How do I buy shares of UCB? Shares of UCBJF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:UCBJF) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UCB SA Please log in to your account or sign up in order to add this asset to your watchlist. Share UCB With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.